Korean Exosome Therapy for Skin in Korea: Complete Guide for International Patients (2026)

Exosome therapy in Korea uses nano-sized vesicles secreted from stem cells (typically umbilical cord-derived MSCs) to deliver growth-factor signaling into skin — but regulatory status is research-grade and clinical evidence remains early-stage.

How Exosomes Differ from PRP

Exosomes are 30 to 150 nanometer extracellular vesicles secreted by cells, carrying proteins, lipids, and microRNAs. They differ from PRP in requiring no blood draw and providing defined growth-factor cargo from cultured stem cells.

Regulatory Status and FDA Position

The FDA has issued warnings against marketing exosomes for clinical indications outside approved trials. Europe and Korea regulate exosomes as research-grade biological products. International patients should confirm product source and certification.

FAQ

Is exosome therapy FDA-approved?

Not as a clinical treatment in the United States. The FDA has issued warnings against unapproved exosome marketing. In Korea, exosomes are used under physician supervision as research-grade products.

Sources

Sources: FDA Exosome Statement, PubMed Exosome Skin Therapy, KHIDI.

Last medically reviewed: 2026-05-23. General educational information for international patients, not medical advice. Consult a board-certified physician.